The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes.
The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes.
复制标题
DOI：
10.2337/dc13-1527
复制
发表时间：
2014-04
期刊：
影响因子：
16.2
通讯作者：
TINSAL-T2D Research Consortium
中科院分区：
文献类型：
--
作者：
Barzilay JI;Jablonski KA;Fonseca V;Shoelson SE;Goldfine AB;Strauch C;Monnier VM;TINSAL-T2D Research Consortium
双水杨酯是一种非乙酰化的水杨酸盐，可降低2型糖尿病（T2D）患者的血糖水平。在此我们研究了双水杨酯是否也会降低与糖尿病血管并发症有关的早期和晚期糖基化终产物（AGEs）的血清蛋白结合水平。
参与者来自使用双水杨酯治疗2型糖尿病的靶向炎症（TINSAL - T2D）研究，该研究检测了双水杨酯治疗对糖化血红蛋白（HbA1c）以及多种其他参数的影响。118名参与者接受双水杨酯治疗，剂量为每天3.5克，持续48周，109名接受安慰剂。在患者血清样本中测量了早期糖基化产物水平（HbA1c和果糖赖氨酸[以呋喃糖氨酸测量]）以及AGE水平（乙二醛和甲基乙二醛氢咪唑酮[G - 1H，MG - 1H]、羧甲基赖氨酸[CML]、羧乙基赖氨酸[CEL]、戊糖素）。
与安慰剂相比，48周的双水杨酯治疗降低了HbA1c、血清呋喃糖氨酸（P < 0.001）以及CML的水平。AGEs中的CEL、G - 1H和MG - 1H水平未改变，而戊糖素水平增加了两倍多（P < 0.001）。在使用双水杨酯的患者中，随访期间脂联素水平的升高与HbA1c水平的降低有关（P < 0.001）。肾脏和炎症因子水平的变化与早期或晚期糖基化因子水平的变化无关。戊糖素水平的变化与肾功能、炎症或细胞因子水平的变化无关。
双水杨酯治疗与早期糖基化终产物的减少有关，但与晚期糖基化终产物无关。血清戊糖素水平出现反常升高，提示氧化应激增加或戊糖素前体的清除减少。
Salsalate is a nonacetylated salicylate that lowers glucose levels in people with type 2 diabetes (T2D). Here we examined whether salsalate also lowered serum-protein-bound levels of early and advanced glycation end products (AGEs) that have been implicated in diabetic vascular complications. Participants were from the Targeting Inflammation Using Salsalate for Type 2 Diabetes (TINSAL-T2D) study, which examined the impact of salsalate treatment on hemoglobin A1c (HbA1c) and a wide variety of other parameters. One hundred eighteen participants received salsalate, 3.5 g/day for 48 weeks, and 109 received placebo. Early glycation product levels (HbA1c and fructoselysine [measured as furosine]) and AGE levels (glyoxal and methylglyoxal hydroimidazolones [G-1H, MG-1H], carboxymethyllysine [CML], carboxyethyllysine [CEL], pentosidine) were measured in patient serum samples. Forty-eight weeks of salsalate treatment lowered levels of HbA1c and serum furosine (P < 0.001) and CML compared with placebo. The AGEs CEL and G-1H and MG-1H levels were unchanged, whereas pentosidine levels increased more than twofold (P < 0.001). Among salsalate users, increases in adiponectin levels were associated with lower HbA1c levels during follow-up (P < 0.001). Changes in renal and inflammation factor levels were not associated with changes in levels of early or late glycation factors. Pentosidine level changes were unrelated to changes in levels of renal function, inflammation, or cytokines. Salsalate therapy was associated with a reduction in early but not late glycation end products. There was a paradoxical increase in serum pentosidine levels suggestive of an increase in oxidative stress or decreased clearance of pentosidine precursor.
登录
查看更多内容
影响因子：
39.2
作者：
Goldfine AB;Fonseca V;Jablonski KA;Chen YD;Tipton L;Staten MA;Shoelson SE;Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team
通讯作者：
Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team
影响因子：
39.2
作者：
Goldfine AB;Fonseca V;Jablonski KA;Pyle L;Staten MA;Shoelson SE;TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team
通讯作者：
TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team
影响因子：
3.5
作者：
SINCLAIR, AJ;TAYLOR, PB;BARNETT, AH
通讯作者：
BARNETT, AH
影响因子：
16.2
作者：
Fleischman, Amy;Shoelson, Steven E.;Goldfine, Allison B.
通讯作者：
Goldfine, Allison B.
影响因子：
4.8
作者：
Fan, Xingjun;Zhang, Jianye;Monnier, Vincent M.
通讯作者：
Monnier, Vincent M.